Summit Therapeutics presents updated HARMONi OS data showing consistent survival benefit with ivonescimab; BLA PDUFA Nov 14, 2026
Summit Therapeutics announced updated HARMONi Phase III overall survival results showing a consistent OS benefit for ivonescimab plus chemotherapy versus placebo plus chemotherapy.Key Highlights:Original SEC Filing: Summit Therapeutics Inc. [ SMMT ] - 8-K - Sep. 15, 2026This is an AI-powered summar…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.